Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective

Pishko AM, Smith KJ, Ragni MV

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1160/TH12-03-0185

Original Paper URL
http://www.schattauer.de/en/magazine/subject-areas/journals-a-z/thrombosis-and-haemostasis/contents/archive/issue/1562/manuscript/17707.html

Indexing Status
Subject indexing assigned by NLM

MeSH
Ambulatory Care; Anticoagulants /economics /therapeutic use; Cohort Studies; Cost-Benefit Analysis; Health Care Costs; Heparin, Low-Molecular-Weight /therapeutic use; Humans; Markov Chains; Models, Economic; Models, Theoretical; Neoplasms /complications /economics /therapy; Probability; Review Literature as Topic; Risk; Time Factors; United States; Venous Thromboembolism /complications /economics /therapy

AccessionNumber
22012029608

Date bibliographic record published
17/10/2012